PCRX Stock Analysis: Buy, Sell, or Hold?
PCRX - Pacira BioSciences, Inc. Common Stock
$24.67
0.84 (3.52%)
▲
5d:
+7.26%
30d:
-4.86%
90d:
+5.07%
BUY
HIGH Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 04, 2026
0d
Get Alerted When PCRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: PCRX shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: PCRX shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$40.22
Based on 11.9% avg growth
INTRINSIC VALUE TODAY
$24.97
1.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 6.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PCRX is currently trading at $24.67, which is considered fair relative to its 30-day fair value range of $24.03 to $26.47. The stock's valuation (Forward PE: 6.9) is in line with its historical norms (6.7). At these levels, the market is pricing in 0.9% annual earnings growth.
Technical Outlook: Technically, PCRX is in a uptrend. The price is approaching resistance at $25.25. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.5% recently.
Market Sentiment: PCRX scores 77/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $30.00 (+25.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PCRX is in a uptrend. The price is approaching resistance at $25.25. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.5% recently.
Market Sentiment: PCRX scores 77/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $30.00 (+25.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$24.03 -
$26.47
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
91.4%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (77/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.5%)
- BULLISH: Trading 25.9% below Wall St target ($30.00)
- BULLISH: Expecting earnings turnaround to 0.9% growth with 6.2% revenue growth
- BULLISH: Bottoming setup score 77/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$24.03 -
$26.47
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$22.79
Resistance Level
$25.25
Current Trend
Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
6.91
Wall Street Target
$30.00
(+25.9%)
Revenue Growth (YoY)
6.2%
Earnings Growth (YoY)
-30.0%
Profit Margin
2.0%
Valuation Premium vs History
+0.9% premium
PE vs Historical
6.9 vs 6.7
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.9%
(market-implied from PE analysis)
1-Year Target
$24.04
(+1%)
2-Year Target
$24.26
(+2%)
3-Year Target
$24.48
(+3%)
3-Yr Target (if PE normalizes)
(PE: 7→7)
PE COMPRESSION
$23.74
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.1, Growth: 19.7%)
$118.61
(+398%)
Base:
(SPY PE: 6.9, Growth: 19.7%)
$40.82
(+71%)
Bear:
(PE: 5.9, Growth: 19.7%)
$34.70
(+46%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (9x PE), but valuation improves significantly next year (7x PE) as earnings recover.
Forward PE: 8.73 | Forward EPS (Implied): $2.83
Bull Case
$29.79
(+21%)
Analyst growth 15.0%, PE expands to 9.2
Base Case
$24.67
(0%)
Market implied 0.0%, PE stable at 8.7
Bear Case
$18.87
(-24%)
Severe decline -15.0%, PE contracts to 7.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 23, 2026 8:27 AM ET
Data refreshes hourly during market hours. Next update: 9:27 AM
Data refreshes hourly during market hours. Next update: 9:27 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PCRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
Shawn Cross
SELL
12941 shares
2026-04-23
Shawn Cross
SELL
1500 shares
2026-04-22
Shawn Cross
SELL
2845 shares
2026-04-21
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$212 | 67 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$107 | 56 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$101 | 43 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$653 | 48 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 55 HOLD |
